



Universiteit
Leiden
The Netherlands

Trial@home for children: novel non-invasive methodology for the pediatric clinical trial of the future

Kruizinga, M.D.

Citation

Kruizinga, M. D. (2022, February 10). *Trial@home for children: novel non-invasive methodology for the pediatric clinical trial of the future*. Retrieved from <https://hdl.handle.net/1887/3274248>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3274248>

Note: To cite this publication please use the final published version (if applicable).

Pharmacokinetics of intravenous and inhaled salbutamol and tobramycin: an exploratory study to investigate the potential of exhaled breath condensate as a matrix for pharmacokinetic analysis

Br J Clin Pharmacol. 2020 Jan;86(1):175–181. doi:10.1111/bcp.14156.

MD Kruizinga,¹ WAJ Birkhoff,¹ MJ van Esdonk,^{1,2} NB Klarenbeek,¹ T Cholewinski,¹ T Nelemans,¹ MJ Dröge,³ AF Cohen,¹ RGJA Zuiker¹

- 1 Centre for Human Drug Research, Leiden, the Netherlands
- 2 Division of Systems Biomedicine and Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands
- 3 Ardena Bioanalytical Laboratory bv, Assen, the Netherlands

Abstract

Concentrations of drugs acting in the lungs are difficult to measure, resulting in relatively unknown local pharmacokinetics. The aim of this study is to assess the potential of exhaled breath condensate (EBC) as a matrix for pharmacokinetic analysis of inhaled and intravenous medication. A 4-way crossover study was conducted in 12 volunteers with tobramycin and salbutamol intravenously and via inhalation. EBC and plasma samples were collected post-dose and analyzed for drug concentrations. Sample dilution, calculated using urea concentrations, was used to estimate the epithelial lining fluid concentration. Salbutamol and tobramycin were largely undetectable in EBC after intravenous administration and were detectable after inhaled administration in all subjects in 50.8% and 51.5% of EBC samples, respectively. Correction of EBC concentrations for sample dilution did not explain the high variability. This high variability of EBC drug concentrations seems to preclude EBC as a matrix for pharmacokinetic analysis of tobramycin and salbutamol.

Introduction

Pharmacological activity is usually derived from the time course of plasma concentrations and pharmacodynamic endpoints for pulmonary drugs, information about local concentrations could potentially improve pharmacokinetic analysis, since pharmacological activity depends on adequate drug levels at the effect site². Lung penetration studies rely on bronchoalveolar lavage (BAL) or sputum induction techniques for the measurement of drugs in the epithelial lining fluid (ELF) of the lung^{3,4}. BAL is invasive and potentially risky, which discourages use in vulnerable patients, children, and healthy subjects. Therefore, new sampling matrices are needed. A matrix of interest is exhaled breath condensate (EBC)⁵. EBC is obtained by cooling exhaled breath through contact with a cold condenser. Samples are collected as fluid or frozen material and represent the ELF, diluted in condensed water from inhaled air and some saliva⁶⁻⁸. EBC application for biomarker quantification has been limited by poor reproducibility and high variability⁹. Several solutions have been proposed to improve reliability of EBC, such as to control for sample dilution factor, obtained via EBC urea concentrations¹⁰⁻¹². Drug concentrations have already been measured in exhaled breath following administration of several drugs¹³⁻¹⁸. Nonetheless, no studies have assessed EBC concentrations after inhaled administration or reported proper concentration-time curves of EBC. The aim of this study is to assess the potential of EBC as a matrix for pharmacokinetic analysis of two common respiratory drugs: salbutamol and tobramycin.

Materials and Methods

This study was conducted at the Centre of Human Drug Research (CHDR) in Leiden, the Netherlands from January 2018 until November 2018. The study protocol was reviewed and approved by the Beoordeling Ethiek Biomedisch Onderzoek (BEBO) Foundation Review Board (Assen, the Netherlands) prior to initiation of the study. The study was conducted according to the Dutch Act on Medical Research Involving Human Subjects (WMO) and in compliance with Good Clinical Practice. Twelve healthy, non-smoking male subjects aged 18–65 years and body mass index (BMI) between 18 and 35 kg/m² were included in this study. Subjects with a history or evidence of lung disease were excluded from this study.

Study design

This was an open-label, 4-way crossover study. Visits were planned with a washout period of 3–7 days. Salbutamol and tobramycin were determined suitable medication to use in this proof-of-concept study, because they are commonly used, are available for intravenous use and inhalation, and have ample data available regarding plasma pharmacokinetics. Subjects were administered 1 mg/kg tobramycin iv (Obracin diluted in 50–100 mL 0.9% NaCl) over 30 minutes, 250 or 500 µg salbutamol by intravenous infusion (Ventolin Injection 0.5 mg/mL) over 2–8 minutes, 170 mg tobramycin (Vantobra) by inhalation using a Medix AC2000® nebulizer (Clement Clarke International) or 400 µg salbutamol (Ventolin Evohaler, GSK, London, UK) by inhalation with a spacer device (Volumatic). Paired EBC and plasma samples were collected at 2 (salbutamol) or 15 and 5 (tobramycin) minutes pre-dose and at 10-, 20-, 40-, 60-, 80-, 120-, 180-, 240-, 300- and 420-minutes post-dose. Additional plasma and EBC samples were collected from 8 subjects at 600- and 720-minutes post-dose after inhaled administration.

Sample collection and analysis

EBC was collected according to European Respiratory Society (ERS) guidelines during 5 minutes of tidal breathing using the Ecoscreen (Jaeger, Hoechst, Germany)¹⁹. EBC samples were stored at -80°C until further analysis. A Liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay was developed by Ardena Bioanalytical Laboratory to quantify tobramycin and salbutamol in plasma and EBC, and urea in EBC (Supplementary Text 1). Urea concentrations were measured as a marker for dilution. At the start of each study day, plasma urea concentration was determined. Dilution factor was calculated ($D_{\text{EBC}} = [\text{urea}]^{\text{PLASMA}} / [\text{urea}]_{\text{EBC}}$) and was multiplied with EBC tobramycin or salbutamol concentration to get a dilution corrected EBC concentration. The coefficient of variation (CV) was calculated per time point until 180 minutes post-dose and compared to the CV before correction.

Statistics and pharmacokinetic analysis

As this was an exploratory study, no formal power analysis was performed. Pharmacokinetic endpoints were summarized descriptively. When tobramycin or salbutamol was

undetectable, 50% of the lowest estimated concentration was imputed for graphical and statistical purposes. Descriptive analysis was performed using SPSS Version 25 (IBM, Armonk, NY). Pharmacokinetic parameters were calculated using R version 3.5.2²⁰. The area under the curve (AUC) was calculated as $AUC_{0-\text{LAST}}$ for EBC parameters and extrapolated to infinity (AUC_{INF}) for plasma parameters using the terminal elimination rate constant, determined by the log-linear regression of the last observations above the LLOQ. The bioavailability (F) was calculated on an individual level and summarized descriptively. When insufficient data was available for the log-linear regression, the AUC_{INF} was not included in the results and the mean AUC_{INF} was imputed for the calculation of the bioavailability (F). The clearance and volume of distribution were calculated and corrected for by an individual's F. Promasys® software (OmniComm, Ft. Lauderdale, FL, USA) was used for data management.

Results

Subjects, safety and tolerability

Twelve healthy male volunteers were included, and all subjects completed the four study days. Baseline characteristics are shown in *Table 1*. Twelve subjects received 1 mg/kg tobramycin by intravenous infusion, 250 µg (3 subjects) or 500 µg (9 subjects) salbutamol by intravenous infusion, 170 mg tobramycin by inhalation and 400 µg salbutamol by inhalation.

Table 1: Baseline characteristics of participants

Demographic	Value
Male, n (%)	12 (100)
Age (years)	24.6 (6.8)
BMI (kg m ⁻²)	22.5 (2.6)
Height (cm)	184 (10.1)
Weight (kg)	75.8 (11.4)
RACE, N (%)	
White	11 (91.7)
Asian	1 (8.3)

Data is presented as mean (standard deviation) unless stated otherwise. All participants completed the four treatment days. BMI: Body Mass Index.

Table 2: Pharmacokinetic parameters mean (standard deviation) [range]

Parameter	Tobramycin Intra-venous (1 mg/kg) ^a	Tobramycin Inhalation (170 mg)	Salbutamol Intra-venous* (500 µg)	Salbutamol inhalation (400 µg)	
PLASMA	t _{MAX} (h)	0.09 (0.02) [0.08-0.17]	2.72 (1.9) [1.33-7.0]	0.04 (0.02) [0.03-0.10]	0.31 (0.14) [0.17-0.69]
	C _{MAX} (ng/ml/pg/ml) ^b	5753.3 (1055.2) [4030-7090]	123.2 (55.7) [50.5-247]	17133.3 (4637.1) [10600-248000]	1012.5 (615.1) [486-2600]
	AUC _{INF} (ng*h/mL/pg*h/mL)	14232.8 (1682.8) [11736.2-17036.2]	1090.34 (389.1) [337.7-1715.4]*	19274.4 (4593.0) [13511-26835]	4128.7 (2487.8) [1588.3-10842.9]
	t _{1/2} (hours)	2.23 (0.25) [1.72-2.68]	4.2 (0.63) [3.09-5.08]*	4.43 (0.87) [3.64-5.96]	4.04 (1.15) [2.04-5.89]
	Volume of distribution (L)	17.26 (3.28) [12.23-22.76]	31.1 (4.0) [25.8-36.5]*	168.4 (22.5) [134.12-194.78]	143.4 (57.6) [70.6-262.5]
	Clearance (L/h)	5.39 (0.99) [3.83-6.88]	5.2 (1.0) [3.8-6.9]*	27.23 (6.25) [18.63-37.01]	25.22 (7.75) [8.3-37.01]
	F (%)	-	3.4 (1.1) [1.4-5.5]	-	22.5 (8.5) [10.7-40.6]c
	EBC samples > LLOQ (%) ^o	-	51.5	2.5	50.8
EBC	EBC AUC _{0-LAST} (ng*h/mL/pg*h/mL)	-	8.39 (5.1) [2.39-16.98]	-	260.3 (224.9) [32.2-645.0]
	EBC C _{MAX} (ng/ml/pg/ml) ^a	-	5.23 (4.78) [0.7-15.2]	-	336.25 (468.74) [25.9-1440]
	EBC t _{MAX} (h)	-	2.60 (4.0) [0.17-10.1]	-	1.36 (3.39) [0.12-12.1]
	CV ^d Before correction for D _{EBC}	-	114 (24)	-	124 (28)
	After correction for D _{EBC}	-	129 (32)	-	144 (40)

a Mean dose: 75 mg; b Salbutamol concentrations are reported as pg/ml, tobramycin concentrations are reported as ng/ml; c Calculated on n=9; d Mean CV calculated for all time points until 180 minutes post dose. Abbreviations: AUC: Area Under the Curve, F: bioavailability, D: dilution

Pharmacokinetics

Mean (\pm SD) plasma and EBC concentration-time curves of all subjects after intravenous and inhaled administration of tobramycin and salbutamol are shown in Figure 1. Pharmacokinetic parameters are summarized in Table 2. Individual concentration-time curves can be found in Supplementary Figure S1 and S2. One subject had an unexplained increase > 2 SD in salbutamol concentration in one plasma sample 2 hours after intravenous infusion, which was excluded during the analysis. After intravenous administration, tobramycin concentrations were undetectable in EBC and a quantifiable concentration of salbutamol was found in only 3 EBC samples (2.5%). However, measurable concentrations of

tobramycin and salbutamol after inhaled administration were present in EBC samples of all subjects. Salbutamol was undetectable in 75% of subjects after 120 minutes. The proportion of samples with a quantifiable concentration of salbutamol per time point ranged from 8–92% (Supplementary Figure S3).

Urea and dilution

Urea concentration was measured in all EBC samples with a quantifiable drug concentration. Individual urea concentrations and D_{EBC} estimates are displayed in Supplementary Figure S4. Mean D_{EBC} was 531 (range 32–5719). Concentration-time curves of the estimated ELF drug concentration are displayed in Figure 1. The mean coefficient of variation (CV) per time point after correction for dilution was 144% (SD 40%) for salbutamol, compared to 124% (SD 28%) before correction. Mean CV of tobramycin concentration after correction was 129% (SD 32%), compared to a prior 114% (SD 24%).

Discussion


In this study, the potential of EBC as a matrix for pharmacokinetic analysis of drugs acting in the lungs was investigated. A 4-way crossover study was conducted wherein we obtained serial paired plasma and EBC samples after intravenous and inhaled administration of tobramycin and salbutamol.

The plasma pharmacokinetics after administration of intravenous and inhaled salbutamol and tobramycin were determined. Calculated pharmacokinetic parameters of salbutamol in plasma corresponded with results reported in other studies regarding T_{MAX}, C_{MAX} and half-life^{21,22}. Plasma C_{MAX} of inhaled tobramycin was lower than expected, which may be a result of the chosen administration technique²³.

We are the first to report serial EBC drug concentrations. We were unable to measure salbutamol and tobramycin in EBC after intravenous administration of salbutamol and tobramycin in 97.5% and 100% of the samples, respectively. Low concentrations were expected in the case of tobramycin, considering the fact that tobramycin is a large (molecular weight 467.52 g/mol), polarized molecule and therefore does not easily pass barriers. This is illustrated by the poor bioavailability of inhaled tobramycin. However, we expected salbutamol to be detectable in more samples, considering salbutamol is a smaller molecule (molecular weight 239.32 g/mol) and the fact that several researchers have

demonstrated the ability to detect intravenously or orally administered drugs with similar properties in exhaled breath or EBC¹³⁻¹⁶. We assume that salbutamol plasma concentrations were insufficient after administration in order to achieve EBC salbutamol concentrations larger than the LLOQ, even with the high dose of 500 µg iv. This hypothesis should be confirmed with a more sensitive assay with a lower LLOQ.

Figure 1. Plasma and EBC concentration–time curves after intravenous administration of tobramycin and salbutamol. A. Concentration–time curve of mean tobramycin concentration in plasma (±SD) after intravenous administration of 1 mg/kg tobramycin (n=12); B. Concentration–time (Mean±SD) curve of plasma (solid line) and EBC (dotted line) tobramycin concentration after inhalation of 170 mg tobramycin; C. Concentration–time curve of mean (SD) EBC tobramycin concentration after inhaled administration of 170 mg tobramycin, corrected for sample dilution; D. Concentration–time curve of mean salbutamol concentration in plasma (±SD) after intravenous administration of 500 µg salbutamol (n=9); E. Concentration–time (Mean±SD) curve of plasma (solid line) and EBC (dotted line) tobramycin concentration after inhalation of 400 µg salbutamol; F. Concentration–time curve of mean (SD) EBC salbutamol concentration after inhaled administration of 400 µg salbutamol, corrected for sample dilution; Sample concentrations < LLOQ were estimated when possible or fixed on 50% of the lowest concentration. Dots represent individual measurements.



Salbutamol and tobramycin were detected in EBC after inhalation of 400µg salbutamol and 170 mg of tobramycin. Mean salbutamol concentrations in EBC after inhaled administration decreased below the LLOQ after approximately two hours, which is about 50% of the amount of time salbutamol is believed to have an effect on pulmonary function²⁴. Furthermore, the highest EBC salbutamol concentrations were present during the absorption

phase of salbutamol in plasma after inhaled administration. This indicates higher EBC concentrations are detected when there is active exchange of salbutamol between the inhaled air, ELF and plasma. However, variability in EBC was high as shown in the supplementary individual plots.

Mean EBC tobramycin concentration decreased sharply in the first hour, which correlated with the duration of the absorption phase in plasma. After the first hour, tobramycin concentrations remained stable or below the LLOQ. This may correspond with the relatively long half-life (4.2 hours) of tobramycin in plasma after inhaled administration compared to the half-life after intravenous administration (2.3 hours). Possibly, ELF acts as a tobramycin reservoir enabling flip-flop kinetics, with tobramycin gradually diffusing towards the systemic circulation. This causes a longer elimination phase, while tobramycin also remains detectable in the diluted ELF that is EBC.

After all, EBC reflects a dilution of the ELF^{8,19}. Variation in dilution factors of EBC samples has been a frequently hypothesized cause of variability. Urea has been proposed as marker for dilution in EBC^{12,25}. We measured urea concentrations in EBC and calculated the estimated dilution. Mean D_{EBC} was slightly lower than reported in other studies^{10,25,26} and varied greatly between and within subjects (Supplementary Figure S4), providing an explanation for the observed variability. The CV increased after correction, which did not meet our hypothesis regarding reduced variability.

EBC research in general has been plagued by high variability within and between subjects^{9,19,30}. While several authors have reported methods to reduce variability^{10-12,25}, this too is poorly reproducible and has not resulted in the development of clear guidelines with standardized methods¹⁹. Consequently, EBC has not yet reached clinical practice. The fact that two commonly used respiratory drugs could not be detected in EBC for the majority of samples post inhalation appears to disqualify EBC as a matrix for pharmacokinetic analysis.

This study has limitations. Variation in inhalation technique could explain the lower than expected plasma concentrations of tobramycin, but also the variability in measured EBC concentrations³¹. In addition, although the EBC device contains a saliva trap, it cannot not be excluded that samples taken directly after administration represent oropharyngeal salbutamol deposition rather than lung pharmacokinetics. Furthermore, almost all sample concentrations were below or on the lower end of the calibration curve. Variability may therefore also result from assay variability as opposed to biological or device variability⁷. Finally, the method to incorporate estimated sample concentrations below the

LLOQ, as well as impute 50% of the lowest concentration when no estimation was possible, is a debated subject³². Nevertheless, the use of other methods would not change the main outcome of this study. A main strength of this study is the longitudinal analysis of EBC concentration and EBC dilution. The 4-way crossover design allowed for the calculation of the bioavailability of tobramycin and salbutamol on an individual level. Finally, EBC collection was conducted in a standardized manner in line with ERS guidelines¹⁹.

Conclusion

In conclusion, salbutamol and tobramycin can be quantified in EBC after inhaled administration, especially during the plasma absorption phase, but not after intravenous administration. The high amount of variability of EBC drug concentrations seems to preclude its use for robust pharmacokinetic analysis and as such, we do not recommend its use in this area.

SUPPLEMENTARY DATA



Sup. Text S1	Sample analysis
Sup. Figure S1	Individual concentration-time curves-inhaled tobramycin
Sup. Figure S2	Individual concentration-time curves-inhaled salbutamol
Sup. Figure S3	Proportion of samples above lower limit of detection
Sup. Figure S4	Individual plots concentration-time curve urea and estimated dilution

REFERENCES

- Lipworth BJ. Pharmacokinetics of inhaled drugs. *Br J Clin Pharmacol*. 1996;42(6):697-705.
- Rizk ML, Zou L, Savic RM, Dooley KE. Importance of Drug Pharmacokinetics at the Site of Action. *Clin Transl Sci*. 2017;10(3):133-42.
- Chandorkar G, Huntington JA, Gotfried MH, Rodvold KA, Umeh O. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. *J Antimicrob Chemother*. 2012;67(10):2463-9.
- van Hasselt JG, Rizk ML, Lala M, Chavez-Eng C, Visser SA, Kerbusch T, *et al*. Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid. *Br J Clin Pharmacol*. 2016;81(6):1113-23.
- Khoubnasabjafari M, Rahimpour E, Samini M, Jouyban-Gharamaleki V, Chen L, Chen DH, *et al*. A new hypothesis to investigate bioequivalence of pharmaceutical inhalation products. *Daru*. 2019;27(1):517-24.
- Sidorenko GI, Zborovskii EI, Levina DI. [Surface-active properties of the exhaled air condensate (a new method of studying lung function)]. *Ter Arkh*. 1980;52(3):65-8.
- Davis MD, Montpetit A, Hunt J. Exhaled breath condensate: an overview. *Immunol Allergy Clin North Am*. 2012;32(3):363-75.
- Effros RM, Peterson B, Casaburi R, Su J, Dunning M, Torday J, *et al*. Epithelial lining fluid solute concentrations in chronic obstructive lung disease patients and normal subjects. *J Appl Physiol* (1985). 2005;99(4):1286-92.
- van Mastriigt E, de Jongste JC, Pijnenburg MW. The analysis of volatile organic compounds in exhaled breath and biomarkers in exhaled breath condensate in children-clinical tools or scientific toys? *Clin Exp Allergy*. 2015;45(7):1170-88.
- Effros RM, Biller J, Foss B, Hoagland K, Dunning MB, Castillo D, *et al*. A simple method for estimating respiratory solute dilution in exhaled breath condensates. *Am J Respir Crit Care Med*. 2003;168(12):1500-5.
- Reinhold P, Knobloch H. Exhaled breath condensate: lessons learned from veterinary medicine. *J Breath Res*. 2010;4(1):017001.
- Esther CR, Jr., Boysen G, Olsen BM, Collins LB, Ghio AJ, Swenberg JW, *et al*. Mass spectrometric analysis of biomarkers and dilution markers in exhaled breath condensate reveals elevated purines in asthma and cystic fibrosis. *Am J Physiol Lung Cell Mol Physiol*. 2009;296(6):L987-93.
- Khoubnasabjafari M, Ansarin K, Jouyban-Gharamaleki V, Panahi-Azar V, Hamidi S, Azarmir Z, *et al*. Methadone Concentrations in Exhaled Breath Condensate, Serum and Urine of Patients Under Maintenance Treatment. *Iran J Pharm Res*. 2017;16(4):1621-30.
- Beck O, Sandqvist S, Bottcher M, Eriksen P, Franck J, Palmeskog G. Study on the sampling of methadone from exhaled breath. *J Anal Toxicol*. 2011;35(5):257-63.
- Gamez G, Zhu L, Disko A, Chen H, Azov V, Chingin K, *et al*. Real-time, in vivo monitoring and pharmacokinetics of valproic acid via a novel biomarker in exhaled breath. *Chem Commun (Camb)*. 2011;47(17):4884-6.
- Perl T, Carstens E, Hirn A, Quintel M, Vautz W, Nolte J, *et al*. Determination of serum propofol concentrations by breath analysis using ion mobility spectrometry. *Br J Anaesth*. 2009;103(6):822-7.
- Hamidi S, Khoubnasabjafari M, Ansarin K, Jouyban-Gharamaleki V, Jouyban A. Chiral separation of methadone in exhaled breath condensate using capillary electrophoresis. *Anal Methods-Uk*. 2017;9(15):2342-50.
- Jouyban A, Samadi A, Khoubnasabjafari M, Jouyban-Gharamaleki V, Ranjbar F. Amidosulfonic acid-capped silver nanoparticles for the spectrophotometric determination of lamotrigine in exhaled breath condensate. *Microchim Acta*. 2017;184(8):2991-8.
- Horvath I, Barnes PJ, Loukides S, Sterk PJ, Hogman M, Olin AC, *et al*. A European Respiratory Society technical standard: exhaled biomarkers in lung disease. *Eur Respir J*. 2017;49(4).
- R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2013 [Available from: <http://www.R-project.org/>].
- Moore A, Riddell K, Joshi S, Chan R, Mehta R. Pharmacokinetics of Salbutamol Delivered from the Unit Dose Dry Powder Inhaler: Comparison with the Metered Dose Inhaler and Diskus Dry Powder Inhaler. *J Aerosol Med Pulm Drug Deliv*. 2017;30(3):164-72.
- Morgan DJ, Paull JD, Richmond BH, Wilson-Evered E, Ziccone SP. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. *Br J Clin Pharmacol*. 1986;22(5):587-93.
- Dalhoff A. Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients. *Clin Microbiol Rev*. 2014;27(4):753-82.
- Filiz A, Ekinci E, Dikensoy O, Bulgur D, Oz M. Comparison of a single dose of aerosol salbutamol and fenoterol/ipratropium on bronchial asthmatic patients. *Del Med J*. 1994;66(10):549-52.
- Effros RM, Hoagland KW, Bosbous M, Castillo D, Foss B, Dunning M, *et al*. Dilution of respiratory solutes in exhaled condensates. *Am J Respir Crit Care Med*. 2002;165(5):663-9.
- Horvath I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, *et al*. Exhaled breath condensate: methodological recommendations and unresolved questions. *Eur Respir J*. 2005;26(3):523-48.
- McCafferty JB, Bradshaw TA, Tate S, Greening AP, Innes JA. Effects of breathing pattern and inspired air conditions on breath condensate volume, pH, nitrite, and protein concentrations. *Thorax*. 2004;59(8):694-8.
- Kullmann T, Barta I, Antus B, Valyon M, Horvath I. Environmental temperature and relative humidity influence exhaled breath condensate pH. *Eur Respir J*. 2008;31(2):474-5.

- 29 Michal Gregus PD, Julia Lacna, Frantisek Foret, Petr Kuban. Study of various parameters that influence the content of exhaled breath condensate used in the diagnosis of gastroesophageal reflux disease. *Hungarian Journal of Industry and Chemistry*. 2018;46(1):29-33.
- 30 Horvath I. The exhaled biomarker puzzle: bacteria play their card in the exhaled nitric oxide-exhaled breath condensate nitrite game. *Thorax*. 2005;60(3):179-80.
- 31 Hindle M, Newton DA, Chrystyn H. Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. *Thorax*. 1993;48(6):607-10.
- 32 Keizer RJ, Jansen RS, Rosing H, Thijssen B, Beijnen JH, Schellens JHM, *et al*. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. *Pharmacol Res Perspe*. 2015;3(2)